Ipamorelin 5 mg — Growth Hormone Secretagogue
Ipamorelin is a highly selective Growth Hormone Secretagogue (GHS) that targets the ghrelin receptor (GHS-R1a) to promote controlled, pulse-like growth hormone (GH) release in research models. Because of its precision and minimal off-target impact, Ipamorelin is widely used to explore metabolic regulation, recovery dynamics, and sleep-linked endocrine rhythms in a laboratory setting.
Within controlled environments, Ipamorelin is valued for its clean profile: low effect on cortisol and prolactin, stable GH-axis activation, and strong compatibility with synergistic peptides such as CJC-1295 and Sermorelin.
Mechanism of Action & Research Findings
Ipamorelin exerts its primary effect by binding selectively to the ghrelin receptor (GHS-R1a). This receptor engagement initiates a signalling cascade that triggers pulsatile GH release from the anterior pituitary, mimicking physiologic secretion patterns without notable stimulation of ACTH or prolactin.
Key Themes
- Stable GH-axis activation with repeatable pulse amplitude.
- Explored in models assessing soft-tissue repair and post-exercise recovery markers.
- Investigated for potential influence on body composition and appetite signalling.
- Studied in relation to sleep architecture and night-time endocrine response patterns.
- Demonstrates enhanced GH pulsatility when paired with GHRH analogues such as CJC-1295 or Sermorelin, allowing combined GHRH/GHRP modelling.
- Minimal impact on cortisol and prolactin in many models, making it a preferred candidate for “clean” GH stimulation studies.
What’s in the Box
- 1 × Ipamorelin 5 mg pre-reconstituted in 2 mL bacteriostatic water (pen-system compatible)
- 1 × replacement needle
Dosage Protocol — Pen System)
The Clinic standardises all cartridges to simplify research use and improve dose reproducibility.
- Pen volume: 3 mL
- Total clicks per pen: 300 clicks
- Ipamorelin content per cartridge: 5 mg
- Calculated strength: 5000 mcg ÷ 300 clicks = 17mcg per click
- Minimum mid-point dose: 10 clicks (250 mcg)
Suggested Dosing
Standard Dose
3 times per day
| Clicks | Dose (mcg) |
|---|---|
| 6 clicks | 100 mcg |
| 9 clicks | 150 mcg |
Pen lasts for: 11 to 17 days
Advanced Dose
3 times per day
| Clicks | Dose (mcg) |
|---|---|
| 15 clicks | 250 mcg |
| 18 clicks | 300 mcg |
Pen lasts for: 6 to 7 days
Frequency & Cycle Length
- Frequency: 2–3 subcutaneous events per day (e.g. AM fasted and/or pre-sleep), depending on study design.
- Cycle length: 8–12 weeks is typically used for meaningful GH-pulse modelling.
Expected Outcomes
Ipamorelin has been associated with:
- Increased frequency and amplitude of GH pulsatility.
- Supportive data for improved tissue repair and post-exercise recovery markers.
- Potential shifts in body-composition parameters under specific protocols.
- Interaction with sleep architecture and night-time GH release patterns.
- Enhanced GH response when combined with CJC-1295 or Sermorelin.
All outcomes remain dependent on model, protocol, and research conditions, and should not be interpreted as therapeutic claims.
